Conjugates with reduced adverse systemic effects

Details Conjugates with reduced adverse systemic effects Conjugates with reduced adverse systemic effects

2005-06-09

2009-06-02

Weber, Jon P (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000, C530S387100, C530S388100, C530S388260, C530S389800, C530S402000, C424S130100, C424S134100

Reexamination Certificate

active

07541330

ABSTRACT:
A conjugate of an active agent and a targeting moiety having affinity for a target cell, in which the active agent has been modified by attachment of a cell membrane-impermeabilizing group so that, if the active agent so modified is cleaved from the conjugate in the blood plasma instead of inside the target cell, the cell membrane-impermeabilizing group prevents or limits entry of the modified active agent into cells, thus reducing its systemic or non-specific adverse effects, including toxicity.

REFERENCES:
patent: 4558139 (1985-12-01), Hagenmaier et al.
patent: 4631190 (1986-12-01), Shen et al.
patent: 4771070 (1988-09-01), Hokanson et al.
patent: 4952394 (1990-08-01), Senter
patent: 5137877 (1992-08-01), Kaneko et al.
patent: 5144011 (1992-09-01), Shen et al.
patent: 5354773 (1994-10-01), Herslof et al.
patent: 5416064 (1995-05-01), Chari et al.
patent: 5708146 (1998-01-01), Willner et al.
patent: 5824805 (1998-10-01), King et al.
patent: 5846545 (1998-12-01), Chari et al.
patent: 5856571 (1999-01-01), Berninger et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5880270 (1999-03-01), Berninger et al.
patent: 5980896 (1999-11-01), Hellstrom et al.
patent: 6008203 (1999-12-01), Magnani et al.
patent: 6214345 (2001-04-01), Firestone et al.
patent: 6281202 (2001-08-01), Magnani et al.
patent: 6333410 (2001-12-01), Chari et al.
patent: 6372712 (2002-04-01), Briesewitz et al.
patent: 6436931 (2002-08-01), Chari et al.
patent: 6441163 (2002-08-01), Chari et al.
patent: 6562785 (2003-05-01), Shapiro
patent: 6759509 (2004-07-01), King et al.
patent: 2003/0055226 (2003-03-01), Chari et al.
patent: 2003/0096743 (2003-05-01), Senter et al.
patent: 2003/0109682 (2003-06-01), Santi et al.
patent: 2004/0018194 (2004-01-01), Francisco et al.
patent: 2004/0126379 (2004-07-01), Adolf et al.
patent: 2004/0219155 (2004-11-01), Thorpe et al.
patent: 2005/0026971 (2005-02-01), Berger et al.
patent: 2005/0232929 (2005-10-01), Kadkhodayan et al.
patent: 0088695 (1983-09-01), None
patent: 0 624 377 (1994-11-01), None
patent: WO 81/01145 (1981-04-01), None
patent: WO 86/01720 (1986-03-01), None
patent: WO 98/13059 (1998-04-01), None
patent: WO 01/24763 (2001-04-01), None
patent: WO 2004/012735 (2004-02-01), None
patent: WO 2004/018000 (2004-03-01), None
Fasken, et al., A leptomycin B-sensitive Homologue of Human CRM1 Promotes Nuclear Export of Nuclear Export Sequence-containing Proteins in Drosophila Cells, The Journal of Biological Chemistry, 2000, vol. 275, No. 3, pp. 1878-1886.
Alberts et al.,Molecular Biology of the Cell, 4th Ed., Garland Science (New York, NY 2002), pp. 739-757.
American Chemical Society, Chemical Substance Reg. No. 87081-35-4, for Leptomycin B.
Carl et al.,J. Med. Chem. 24 (3), 479-480 (1981), “A Novel Connector Linkage Applicable in Prodrug Design”.
Cooper,The Cell: A Molecular Approach, ASM Press (Washington DC, 1997), pp. 381-383, 492-500.
Doronina et al.,Nature Biotechnology21 (7), 778-784 (2003) (erratum, p. 941), “Development of Potent Mono-clonal Antibody Auristatin Conjugates for Cancer Therapy”.
Dubowchik et al.,Bioconjugate Chem. 13, 855-869 (2002), “Cathepsin B-Labile Dipeptide Linkers for Lysosomal Release of Doxorubicin from Internalized Immunoconjugates: Model Studies of Enzymatic Drug Release and Antigen-specific in Vitro Anticancer Activity”.
Dubowchik et al.,Bioorg. Med. Chem. Lett., 8, 3347-3352 (1998), “Cathepsin B-Sensitive Dipeptide Prodrugs. 2. Models of Anticancer Drugs Paclitaxel (Taxol®), Mitomycin C and Doxorubicin”.
Dubowchik et al.,Biorg. Med. Chem. Lett. 8, 3341-3346 (1998), “Cathepsin B-Sensitive Dipeptide Prodrugs. 1. A Model Study of Structural Requirements for Efficient Release of Doxorubicin”.
Dubowchik et al., Pharmacology & Therapeutics, 83, 67-123 (1999), “Receptor-Mediated and Enzyme-Dependent Targeting of Cytotoxic Cancer Drugs”.
Gagliardi et al.,J. Med. Chem., 41, 1883-1893 (1998), “Synthesis and Structure-Activity Relationships of Bafilomycin A1Derivatives as Inhibitors of Vacuolar H+-ATPase”.
Garnett,Adv. Drug Delivery Rev., 53, 171-216 (2001), “Targeted drug conjugates: principles and progress”.
Isawa et al.,J. Antibiotics34 (12), 1587-1590 (1981), “Demethylation of Ansamitocins and Related Compounds”.
Kalesse et al.,Synthesis2002, 8, 981-1003, “The Chemistry and Biology of the Leptomycin Family”.
Kawai et al.,Chem. Pharm. Bull., 32 (9), 3441-3451 (1984), “Chemical Modification of Ansamitocins. III. Synthesis and Biological Effects of 3-Acyl Esters of Maytansinol”.
King et al.,J. Med. Chem. 45, 4336-4343 (20020, “Monoclonal Antibody Conjugates of Doxorubicin Prepared with Branced Peptide Linkers: Inhibition of Aggregation by Methoxytriethyleneglycol Chains”.
Kupchan et al.,J. Am. Chem. Soc., 97, 5294-5295 (1975), “Novel Maytansinoids, Naturally Occurring and Synthetic Antileukemic Esters of Maytansinol”.
Kupchan et al.,J. Med. Chem. 21 (1), 31-37 (1978), “Structural Requirements for Antileukemic Activity among the Naturally Occurring and Semisynthetic Maytan-sinoids”.
Mattson et al.,J. Biol. Chem., 269 (40), 24979-24982 (1994), “Isolation and Reconstitution of a Vacuolar-type Proton Pump of Osteoclast Membranes”.
Riddles et al.,Anal Biochem., 94 75-81 (1979), “Ellman's Reagent: 5,5′-Dithiobis(2-nitrobenzoic Acid)—a Reexamination”.
Ritchlin et al.,J. Clin. Investig., 111 (6), 831-831 (2003), “Mechanisms of TNF-α- and RANKL-mediated Osteo-clastogenesis and Bone Resorption in Psoriatic Arthritis”.
Rodan et al.,Science, 289, 1508-1514 (2000), “Thera-peutic Approaches to Bone Diseases”.
Schacht et al., “Macromolecular Carriers for Drug Targeting,” in Wermuth, ed.,The Practice of Medicinal Chemistry, 2nd Ed., pp. 587-600 (Academic Press 2003).
Sekine et al.,J. Am. Chem. Soc., 100, 1001-1002 (1978), “Silyl Phosphites. 6. Reactions of Tri(trimethylsilyl) Phosphite with α-Halocarbonyl Compounds”.
Senter et al.,Proc. Am. Assoc. Cancer Res., 2004, 45, p. 144, abstract No. 623, “Immunoconjugates comprised of drugs with impaired cellular permeability: A new approach to targeted therapy”.
Shen et al.,Biochem. Biophys. Res. Commun. 1981, 102, 1048-1054, “Cis-aconityl Spacer Between Daunomycin and Macromolecular Carriers: a Model of pH-sensitive Linkage Releasing Drug from a Lysosomotropic Conjugate”.
Sundquist et al.,Biochem. Biophys. Res. Commun., 168 (1), 309-313 (1990), “Inhibition of Osteoclast Proton Transport by Bafilomycin A1Abolishes Bone Resorption”.
Toki et al.,J. Org. Chem. 2002, 67, 1866-1872, “Protease Mediated Fragmentation of p-Amidobenzyl Ethers: A New Strategy for the Activation of Anticancer Prodrugs”.
Trouet et al.,Proc. Natl. Acad. Sci. USA, 79, 626-629 (1982), “A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate; In vitro and in vivo studies”.
Vaananen et al.,J. Cell Sci., 113, 377-381 (2000), “The Cell Biology of Osteoclast Function”.
Yoshimori et al.,J. Biol. Chem. 266 (26), 17707-17712 (1991), “Bafilomycin A1, a Specific Inhibitor of Vacuolar-type H+-ATPase, Inhibits Acidification and Protein Degradation in Lysosomes of Cultured Cells”.
Senter et al. Proc. AACR 45, 144, abst. No. 623 (Mar. 2004), “Immunoconjugates Comprised of Drugs with Impaired Cellular Permeability: A new Approach to Targeted Therapy”.

Affiliated with

Also associated with

Rating

Conjugates with reduced adverse systemic effects does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Conjugates with reduced adverse systemic effects, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conjugates with reduced adverse systemic effects will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4145041